Applied UV's Airocide® and Lumicide Address CDC's Recommendation for Handling Environments Contaminated by Monkeypox

Applied UV's Airocide® and Lumicide Address CDC's Recommendation for Handling Environments Contaminated by Monkeypox

Applied UV, Inc. (NasdaqCM: AUVI ) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically affirms that its pathogen killing technology SteriLumen's   Airocide® and Lumicide are highly effective, differentiating solutions for addressing recent recommendations from the Centers for Disease Control (CDC) for cleaning and disinfecting settings that may be contaminated with Monkeypox and other orthopoxviruses.

In a recent publication, available here , the CDC provided considerations for disinfecting settings that may be contaminated with Monkeypox virus and highlighted the virus' sensitive to UV light, disinfectants and household cleaners in a tweet available here .

John F. Andrews Applied UV's CEO and Director stated, "As the only public, pure-play air and surface disinfection company, we are uniquely capable of capturing a significant portion of the emerging market opportunity affirmed by the CDC's recommendations. We have a growing list of business case uses for global, highly recognized customers such as Whole Foods, Del Monte, the Boston Red Sox, Opus One and Tru Infusion, across a diversity of vertical markets including healthcare, cannabis, correctional facilities, schools, wineries, dairy and food preservation that use our Airocide product suite and attest to its efficacy. The emergence of Monkeypox, which is an airborne and surface transmitted pathogen, presents an additional opportunity for us to apply our clinically-proven Airocide and Lumicide technologies to eradicate the virus from virtually any contaminated setting and reduce the risk of spread. Independent research has affirmed that orthopoxviruses, including Monkeypox, can survive in an environment for weeks or months and porous materials may harbor live viruses for longer periods of time. Airocide, which was developed for NASA and the University of Wisconsin at Madison, is more effective than ultra-violet (UV) solutions as it utilizes Photocatalytic Oxidation (PCO) technology to completely trap and destroy any and all carbon-based airborne viruses by oxidation without any harmful by-products, and our patented Lumicide surface and drain UVC technology will destroy any surface related Monkeypox virus. We are encouraged by the CDC's proactive efforts to provide guidance on ways to clean, disinfect and reduce the risk of spread, and we look forward to applying our industry-leading solution to help keep people healthy and safe."

Airocide® System

The Airocide® System, originally developed for NASA with assistance from the University of Wisconsin at Madison, is an airborne pathogen killing technology that uses a patented combination of UVC and a proprietary, titanium dioxide based photocatalyst. Listed as an FDA Class II Medical device, the Airocide® technology is clinically proven and field tested to kill/remove/eliminate airborne pathogenic and non-pathogenic microorganisms, allergens, odors and harmful VOCs in a variety of applications and industries including healthcare, hospitality, grocery chains, wineries, commercial real estate, schools, dental offices and homes. Airocide® air purifiers are available at www.airocide.com .

Follow us on Twitter
Follow us on LinkedIn

About Applied UV

Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide® air purification devices are research backed, clinically proven and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photocatalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities and homes. For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/

Forward-Looking Statements

The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.

For additional Company Information:  
Applied UV Inc.
John F. Andrews
Applied UV CEO, Director
john.andrews@applieduvinc.com

Contact:  
Brett Maas, Managing Principal
Hayden IR
brett@haydenir.com
(646) 536-7331

News Provided by Business Wire via QuoteMedia

AUVI:NSD
The Conversation (0)
XReality Group

Quarterly Activities Report and Appendix 4C - 30 Sept 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following Quarterly Activities Report and Appendix 4C for the quarter ending 30th September 2024 together with an Operational Update.

Keep reading...Show less
Sona Nanotech Issued Patent and Appoints New Board Member

Sona Nanotech Issued Patent and Appoints New Board Member

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the issuance of U.S. Patent No. 12117447 by the U.S. Patent and Trademark Office to the Company, entitled, "Metal Nanoparticles and Methods of Making Same". This patent covers the Company's proprietary process for manufacturing gold nanorods without the use of the toxic substance, cetyltrimethylammonium bromide ("CTAB"), which typically carries significant cytotoxic and genotoxic risks.

The Company is also pleased to announce the appointment of Mr. Wayne Myles, KC, FIIC, to its board of directors. An active investor and entrepreneur, Mr. Myles has served as lead counsel and strategic business advisor on more than 100 domestic and international acquisitions and sales, financings, government and regulatory affairs and licensing mandates. He has significant and diverse experience as a director of public and private companies. He also has been recognized with numerous professional achievements, distinctions and awards, including being named as one of "Canada's Top 25 Most Influential Lawyers' by Canadian Lawyer Magazine."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Four laptops around a device with a quantum symbol inside.

How to Invest in Quantum Computing Companies (Updated 2024)

Quantum computing is an emerging technology that has the potential to revolutionize many industries.

According to a late 2021 Statista forecast, the quantum computing market's total revenue is projected to reach US$8.6 billion by 2027. To put that into perspective, the industry was worth only US$412 million in 2020.

With that in mind, it's clear the field of quantum computing is nascent and exciting. Here the Investing News Network takes a look at what it is, its potential impact on several industries and how investors can get exposure to quantum computing through stocks, startups and exchange-traded funds.

Keep reading...Show less
XReality Group

Additional Funding Secured to Support Order Outlook

xReality Group Limited (“XRG” or the “Company”) is pleased to announce an additional $500,000 debt facility has been secured. The purpose of the additional drawdown is to increase inventory, accelerate the delivery of current projects and meet future orders.

Keep reading...Show less
Mockup of a person with a brain chip like the one Neuralink is creating.

Can You Invest in Elon Musk’s Neuralink? (Updated 2024)

Elon Musk's Neuralink has captured the public’s attention and imagination with its futuristic vision of connecting the human brain to computers.

A July 2024 report by IDTechEx projects that the overall brain computer interface market could reach a market value of over US$1.6 billion by 2045.

"We anticipate that the market for non-invasive solutions will grow before the commercialization of invasive solutions from players such as Neuralink," stated the research firm's Senior Technology Analyst Dr. Tess Skyrme. "However, the long-term opportunity within the assistive technology market is more likely to be captured by the likes of Elon Musk."

As Neuralink continues to make strides, investors are wondering how to get a piece of the action by investing in the neurotechnology venture.

Because it is privately held, Neuralink stock isn't accessible to the average person — but that doesn't mean its impossible to get exposure to this future-looking medical research company. Read on to learn how to participate in the growth of this exciting business.

Keep reading...Show less
E-Power Samples 37% Cg in New Discovery Area and 30% Cg at Advanced Target

E-Power Samples 37% Cg in New Discovery Area and 30% Cg at Advanced Target

E-Power Resources Inc. (CSE: EPR) ("E-Power" or the "Company") is pleased to report additional results from the 2024 exploration program on the Company's flagship Tetepisca flake graphite property located in the North Shore region of Québec.

Highlights include:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×